Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9867863 | LA JOLLA PHARMA | Method of treating low blood pressure |
Dec, 2029
(5 years from now) | |
US10335451 | LA JOLLA PHARMA | Method of treating low blood pressure |
Dec, 2029
(5 years from now) | |
US10548943 | LA JOLLA PHARMA | Method of treating low blood pressure |
Dec, 2029
(5 years from now) | |
US10500247 | LA JOLLA PHARMA | Method of treating low blood pressure |
Dec, 2029
(5 years from now) | |
US9572856 | LA JOLLA PHARMA | Method of treating low blood pressure |
Jul, 2031
(7 years from now) | |
US11096983 | LA JOLLA PHARMA | Angiotensin II alone or in combination for the treatment of hypotension |
Dec, 2034
(10 years from now) | |
US10493124 | LA JOLLA PHARMA | Angiotensin II alone or in combination for the treatment of hypotension |
Dec, 2034
(10 years from now) | |
US9220745 | LA JOLLA PHARMA | Angiotensin II alone or in combination for the treatment of hypotension |
Dec, 2034
(10 years from now) | |
US10028995 | LA JOLLA PHARMA | Angiotensin II alone or in combination for the treatment of hypotension |
Dec, 2034
(10 years from now) | |
US11559559 | LA JOLLA PHARMA | NA |
Dec, 2034
(10 years from now) | |
US11219662 | LA JOLLA PHARMA | Methods for treating hypotension in a patient that has received an ACE inhibitor by administering angiotensin II |
Jan, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Dec 21, 2022 |
NCE-1 date: 2021-12-21
Market Authorisation Date: 21 December, 2017
Treatment: Treating refractory hypotension with about 5 ng/kg/min to about 20 ng/kg/min angiotensin ii in a patient receiving vasopressor; Treating hypotension with about 20 ng/kg/min to about 40 ng/kg/min angio...
Dosage: SOLUTION;INTRAVENOUS